Jane Street’s Global X China Biotech Innovation ETF CHB Stock Holding History

Jane Street’s Portfolio CHB Stock Details CHB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-21,688	Closed	-$176K	–	10400
2023 Q4	$176K	Buy	21,688 +10,459	+93%	+$83.3K	﹤0.01%	8307
2023 Q3	$84.9K	Buy	+11,229	New	+$84.3K	﹤0.01%	8017
2023 Q1	–	Sell	-19,093	Closed	-$180K	–	10244
2022 Q4	$180K	Buy	19,093 +5,864	+44%	+$53.6K	﹤0.01%	7744
2022 Q3	$111K	Buy	+13,229	New	+$133K	﹤0.01%	8595
2022 Q2	–	Sell	-14,549	Closed	-$167K	–	11249
2022 Q1	$167K	Sell	14,549 -2,907	-17%	-$35.5K	﹤0.01%	9153
2021 Q4	$249K	Buy	+17,456	New	+$268K	﹤0.01%	8484
2021 Q3	–	Sell	-25,874	Closed	-$486K	–	10974
2021 Q2	$486K	Sell	25,874 -8,423	-25%	-$154K	﹤0.01%	7299
2021 Q1	$557K	Buy	+34,297	New	+$592K	﹤0.01%	6596

Jane Street's CHB Position: Q1 2024 in Review

Jane Street sold out of Global X China Biotech Innovation ETF (CHB) in Q1 2024, closing a stake of 21,688 shares — an estimated $176K sold.

Jane Street first reported a position in CHB in Q1 2021 and held it in 8 quarters. The position peaked at $557K in Q1 2021. 0 funds tracked by Wall St. Rank hold CHB as of Q1 2024.

Jane Street reported no remaining Global X China Biotech Innovation ETF position as of Q1 2024 after selling out during the quarter.
Jane Street sold 21,688 Global X China Biotech Innovation ETF shares in Q1 2024, an estimated $176K.
Jane Street first reported a position in Global X China Biotech Innovation ETF in Q1 2021 and held it in 8 quarters.
Jane Street's Global X China Biotech Innovation ETF position peaked at $557K in Q1 2021.
0 funds tracked by Wall St. Rank held Global X China Biotech Innovation ETF as of Q1 2024.

Based on Jane Street's 13F filing for Q1 2024, filed 16 May 2024.